Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

very well tolerated in the first dose group. To expedite patient recruitment, Rigel has added additional clinical sites that have significant experience in RA clinical trials. Rigel expects to receive results from the completed clinical trial in the second half of 2007.

Rigel today announced the enrollment of patients in a multi-center, Phase 2 clinical trial to evaluate the safety and efficacy of R788 for the treatment of patients with B-cell lymphoma. Approximately 80% of patients with non- Hodgkin's lymphoma have the B-cell variety, which is characterized by an over- expression of B-cell receptors and the proliferation of B-cells. Research has shown that R788 effectively interrupts the growth of B-cells and signaling proteins that contribute to the survival of these tumors.

The open label clinical trial is expected to enroll a total of approximately 60 patients at 10 major cancer treatment centers in the U.S. and will focus on refractory diffuse large, follicular and mantle B-cell lymphomas. The primary efficacy endpoint will be overall response rate according to standard criteria. Secondary efficacy, safety and pharmacodynamic endpoints, as well as the role of syk activation in predicting responses, will also be measured. Depending on enrollment, results of the clinical trial are expected in 2008.

R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B-cells that promote swelling, inflammatory responses and tissue damage. These activities derive from syk kinase's pivotal role in mediating immunoglobulin signaling inside cells. It is currently being evaluated in two Phase 2 studies with respect to RA and ITP, and enrollment in an additional Phase 2 clinical trial in B-cell lymphoma has commenced. Phase 1 trial results demonstrated that R788 was well tolerated and showed good pharmaceutical properties when administered both alone and, with respect to the treatment of patients with RA, in combinat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... Dec. 23, 2014 In response to urgent requests ... Sierra Leone , Direct Relief delivered two ... for the treatment of local health workers who contract Ebola ... dedicated Ebola care center was constructed for foreign health care ... not available for local Sierra Leonean health workers. ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... December 25, 2014 Plugin creators from ... 5k. A fully customizable business presentation tool made specifically ... the ProFire 5k business tool, users can now display ... CEO of Pixel Film Studios. “ProFire 5k gives users ... to add professionalism to a presentation” , Pixel Film ...
(Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and ... under $150 . All these items are brand new; they ... already been updated with the new range of high quality ... far. All iFitDress.com’s designs are made according to the latest ... materials. Every outfit from the company is handpicked by skilled ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 ... ) that allege the blood thinner caused life-threatening ... outlined a leadership structure for the proceeding, Bernstein ... December 17th, the Court plans to select lawyers ... and also plans on appointing a Plaintiffs’ Steering ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... promises, claimed patients in a survey despite the government promises ... patients survey has found high levels of general satisfaction with ... of the 80,000 people who took part a different picture ... ‘very clean’ as compared to 56% in 2002. While at ...
... the NHS staff should be praised for their efforts and ... the "best ever". He said that the maximum waiting time ... ,Reports indicated that the figures up to 31st ... with an 18-week wait for treatment was at its lowest ...
... in Ranchi, the Jharkhand Health department today said the ... // ,'We have equipped the Sadar hospital ... patients,' Health and Family Welfare's joint secretary R C ... free treatment at the hospital instead of streaming to ...
... world , including India, must face the challenges of ... their citizens get access to effective healthcare // , ... medical expenses, a new World Bank report said. ... to cope with sharply rising costs even while countries ...
... of the anti-quota strike call given by the Indian ... (BMC) // and Government Dental colleges today struck ... services in Victoria and Vani Vilas and government dental ... affected, Dr Venugopal, President, Junior Doctors Assoication, BMC told ...
... 25 (pti) As part of Tsunami relief efforts ... inaugurated at Thennampattinam, a tsunami-hit village in Sirkali ... Wucherer,member, corporate executive committee of Siemens, AG declared ... community and Consulate General, Earthquake assistant foundation through ...
Cached Medicine News:Health News:Quality Of NHS Hospitals Getting Dirtier Despite Promises 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 3
... high end desktop multilaser flow cytometer for ... of cell analysis and absolute counting. The ... two different side scatter signals in combination ... new CyFlow ML instrument can perform in ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
AIA - Nex.IA immunoassay analyzer state of the art automation and flexibility for high throughput immunoassay testing...
Medicine Products: